CPSE:BAVABiotechs
How Investors Are Reacting To Bavarian Nordic (CPSE:BAVA) Securing Health Canada Approval For VIMKUNYA
In late June 2026, Bavarian Nordic announced that Health Canada approved VIMKUNYA, its single-dose, virus-like particle chikungunya vaccine, for individuals 12 years and older, adding Canada to prior approvals in the US, EU, UK and Switzerland.
This fifth regulatory approval broadens preventive options for travelers to chikungunya-endemic regions and highlights growing acceptance of non-infectious VLP vaccines in routine travel health.
Next, we'll examine how Health Canada's approval of...